Mineralys Director Karydas Sells $75,000 in Company Stock
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
insider-tradingbiotech-stocks
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
George K. Karydas, a director at Mineralys Therapeutics, sold shares worth approximately $75,000 on June 17, 2026. The transaction was executed at a price of $10.75 per share, reducing his direct holdings in the clinical-stage biopharmaceutical company. Mineralys is currently advancing lorundrostat, a novel aldosterone synthase inhibitor for treatment-resistant hypertension, through late-stage clinical development.
Insider selling activity often attracts scrutiny, particularly for companies approaching significant clinical milestones. Mineralys Therapeutics is preparing for topline data from its Phase 3 Advance-HTN trial of lorundrostat, expected in the second half of 2026. The trial's outcome will determine the drug's efficacy in controlling blood pressure in resistant hypertension patients and significantly influence the company's valuation and partnership opportunities.
The current biotech funding environment remains challenging, with the SPDR S&P Biotech ETF (XBI) down approximately 5% year-to-date as of June 18, 2026. Rising interest rates have particularly pressured pre-commercialization biotech firms that rely on future capital raises for development funding. Against this backdrop, insider transactions are monitored for signals about management confidence ahead of binary events.
Karydas sold 7,000 shares at $10.75 per share, generating total proceeds of $75,250. Following this transaction, his direct holdings decreased to approximately 42,000 shares. Mineralys Therapeutics maintains a market capitalization of approximately $450 million based on its current share price and outstanding float.
The transaction represents a relatively small portion of the director's overall position, amounting to approximately 14% of his directly held shares. Mineralys stock has traded between $8.50 and $14.20 over the past 52 weeks, placing the sale price near the midpoint of this range. Average daily trading volume for MLYS shares is approximately 120,000 shares, meaning this sale represented about 6% of typical daily liquidity.
Compared to sector peers, insider selling at biotech firms approaching Phase 3 readouts is not uncommon. Companies like Cytokinetics and Madrigal Pharmaceuticals experienced similar insider transactions ahead of their pivotal trial results, with sales typically representing less than 20% of an insider's total position. The magnitude of this sale falls within typical patterns for pre-catalyst transactions.
The sale may prompt questions about director confidence ahead of the critical Phase 3 data readout. However, the relatively small size of the transaction suggests it likely relates to personal financial planning rather than a fundamental negative view on trial outcomes. Institutional investors typically view insider sales below $100,000 as less significant than larger dispositions.
Second-order effects could include increased volatility in MLYS options ahead of the data readout, particularly in near-dated contracts. The implied volatility for options expiring around the expected data release period may increase if additional insider activity emerges. Sector peers focused on cardiovascular diseases, such as Merck (MRK) and Novartis (NVS), could see increased attention as investors assess competitive landscapes.
A counterargument suggests that any insider selling before a binary event warrants caution, as directors typically have superior knowledge about trial progress and company fundamentals. However, regulatory frameworks strictly limit trading during closed periods when material non-public information exists, reducing the likelihood that this sale reflects negative non-public information.
Investors should monitor the expected topline data release from the Advance-HTN trial, currently projected for Q4 2026. The primary endpoint is the change from baseline in systolic blood pressure after 12 weeks of treatment compared to placebo. Secondary endpoints include responder rates and safety profiles that will be crucial for regulatory submissions.
Key levels to watch for MLYS shares include technical support at $9.50, which has held through previous selloffs, and resistance near $12.50, which represents the upper bound of recent trading ranges. A breakout above $13.50 would signal renewed bullish momentum, while a break below $9.00 could indicate deteriorating sentiment.
The FDA's decision on lorundrostat's New Drug Application, expected in 2027 if the trial succeeds, represents the next major catalyst after the Phase 3 readout. Partnership announcements with larger pharmaceutical companies could also materialize following positive data, potentially providing non-dilutive funding for commercialization efforts.
Insider selling in biotech stocks requires contextual interpretation based on transaction size, timing relative to catalysts, and the executive's remaining stake. Sales representing less than 20% of a position, particularly when executed well before binary events, often reflect personal financial needs rather than negative expectations. Large sales immediately before data readouts or by multiple insiders simultaneously typically carry more significance for market sentiment.
Lorundrostat represents a novel mechanism targeting aldosterone synthase inhibition rather than blocking the effects of aldosterone like existing medications such as spironolactone and eplerenone. This approach potentially offers better efficacy in treatment-resistant hypertension patients with fewer side effects related to hormone disruption. The drug specifically targets patients with elevated aldosterone levels, which represents approximately 20-30% of the resistant hypertension population.
The global resistant hypertension market is estimated to reach $15 billion by 2028, with approximately 10-12 million patients worldwide inadequately controlled on current therapies. Lorundrostat's targeted mechanism could capture 5-10% of this market within three years of approval, generating potential peak sales of $750 million to $1.5 billion annually. Mineralys would likely require a commercialization partner to maximize revenue potential in this competitive space.
A director's routine stock sale warrants monitoring but doesn't necessarily signal concerns about upcoming trial data.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.